Compile Data Set for Download or QSAR

Found 3117 hits with Last Name = 'yen' and Initial = 'j'   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Protease (Human immunodeficiency virus 1 (HIV-1))	BDBM50480930 (CHEMBL584130 | KNI-814) Show SMILES Cc1cccc(C)c1CNC(=O)[C@H]1N(CSC1(C)C)C(=O)[C@@H](O)[C@H](Cc1ccccc1)NC(=O)c1cccc(O)c1C |r| Show InChI InChI=1S/C33H39N3O5S/c1-20-11-9-12-21(2)25(20)18-34-31(40)29-33(4,5)42-19-36(29)32(41)28(38)26(17-23-13-7-6-8-14-23)35-30(39)24-15-10-16-27(37)22(24)3/h6-16,26,28-29,37-38H,17-19H2,1-5H3,(H,34,40)(H,35,39)/t26-,28-,29+/m0/s1	PDB UniProtKB/TrEMBL B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	0.00240	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Kyoto Pharmaceutical University Curated by ChEMBL					Assay Description Inhibition of HIV1 recombinant protease after 15 mins by fluorescence assay				J Med Chem 52: 7604-17 (2009) Article DOI: 10.1021/jm9005115 BindingDB Entry DOI: 10.7270/Q2FR00F2
					More data for this Ligand-Target Pair
Protease (Human immunodeficiency virus 1 (HIV-1))	BDBM580 ((4R)-3-[(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylph...) Show SMILES Cc1ccccc1CNC(=O)[C@H]1N(CSC1(C)C)C(=O)[C@@H](O)[C@H](Cc1ccccc1)NC(=O)c1cccc(O)c1C |r| Show InChI InChI=1S/C32H37N3O5S/c1-20-11-8-9-14-23(20)18-33-30(39)28-32(3,4)41-19-35(28)31(40)27(37)25(17-22-12-6-5-7-13-22)34-29(38)24-15-10-16-26(36)21(24)2/h5-16,25,27-28,36-37H,17-19H2,1-4H3,(H,33,39)(H,34,38)/t25-,27-,28+/m0/s1	PDB UniProtKB/TrEMBL B.MOAD GoogleScholar AffyNet	MCE MMDB PC cid PC sid PDB UniChem Similars	PDB Article PubMed	0.0310	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Kyoto Pharmaceutical University Curated by ChEMBL					Assay Description Inhibition of HIV1 recombinant protease after 15 mins by fluorescence assay				J Med Chem 52: 7604-17 (2009) Article DOI: 10.1021/jm9005115 BindingDB Entry DOI: 10.7270/Q2FR00F2
					More data for this Ligand-Target Pair				3D Structure (crystal)
Plasma kallikrein (Homo sapiens (Human))	BDBM50256265 (CHEMBL4089486) Show SMILES CC(C)C[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSCc3cc(CSC[C@H](NC1=O)C(O)=O)cc(CSC[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N1CCC1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)c3 |r| Show InChI InChI=1S/C74H104N20O19S3/c1-36(2)18-49-64(103)88-51(24-44-27-78-35-81-44)66(105)85-48(13-14-59(75)97)63(102)89-52(25-60(98)99)67(106)86-50(19-37(3)4)65(104)93-57(73(112)113)34-116-31-42-21-40-20-41(22-42)30-115-33-56(70(109)87-49)92-62(101)47(12-9-16-79-74(76)77)84-61(100)38(5)82-71(110)58-15-17-94(58)72(111)53(23-43-26-80-46-11-8-7-10-45(43)46)90-68(107)54(28-95)91-69(108)55(32-114-29-40)83-39(6)96/h7-8,10-11,20-22,26-27,35-38,47-58,80,95H,9,12-19,23-25,28-34H2,1-6H3,(H2,75,97)(H,78,81)(H,82,110)(H,83,96)(H,84,100)(H,85,105)(H,86,106)(H,87,109)(H,88,103)(H,89,102)(H,90,107)(H,91,108)(H,92,101)(H,93,104)(H,98,99)(H,112,113)(H4,76,77,79)/t38-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	0.0600	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of platelet derived growth factor receptor beta phosphorylation in MG63 cells in the presence of human plasma				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM50256283 (CHEMBL4079711) Show SMILES CC(C)C[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSCc3cc(CSC[C@H](NC1=O)C(=O)N[C@@H](C)C(O)=O)cc(CSC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)c3 |r| Show InChI InChI=1S/C79H114N22O20S3/c1-38(2)20-52-68(110)94-54(26-47-29-84-37-87-47)70(112)91-51(16-17-62(81)103)67(109)95-55(27-63(104)105)71(113)92-53(21-39(3)4)69(111)100-58(73(115)89-42(7)78(120)121)34-122-31-43-22-44-24-45(23-43)33-124-36-60(74(116)93-52)99-66(108)50(14-10-18-85-79(82)83)90-65(107)41(6)88-76(118)61-15-11-19-101(61)77(119)56(25-46-28-86-49-13-9-8-12-48(46)49)96-72(114)57(30-102)97-75(117)59(35-123-32-44)98-64(106)40(5)80/h8-9,12-13,22-24,28-29,37-42,50-61,86,102H,10-11,14-21,25-27,30-36,80H2,1-7H3,(H2,81,103)(H,84,87)(H,88,118)(H,89,115)(H,90,107)(H,91,112)(H,92,113)(H,93,116)(H,94,110)(H,95,109)(H,96,114)(H,97,117)(H,98,106)(H,99,108)(H,100,111)(H,104,105)(H,120,121)(H4,82,83,85)/t40-,41-,42-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem Similars	Article PubMed	0.0700	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of human plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins followed by substrate additio...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM50256264 (CHEMBL4099333) Show SMILES CC(C)C[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSCc3cc(CSC[C@H](NC1=O)C(O)=O)cc(CSC[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N1CCC1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(N)=N)C(=O)N2)c3 |r| Show InChI InChI=1S/C75H106N20O19S3/c1-37(2)19-50-65(104)89-52(25-45-28-79-36-82-45)67(106)86-49(14-15-60(76)98)64(103)90-53(26-61(99)100)68(107)87-51(20-38(3)4)66(105)94-58(74(113)114)35-117-32-43-22-41-21-42(23-43)31-116-34-57(71(110)88-50)93-63(102)48(13-9-10-17-80-75(77)78)85-62(101)39(5)83-72(111)59-16-18-95(59)73(112)54(24-44-27-81-47-12-8-7-11-46(44)47)91-69(108)55(29-96)92-70(109)56(33-115-30-41)84-40(6)97/h7-8,11-12,21-23,27-28,36-39,48-59,81,96H,9-10,13-20,24-26,29-35H2,1-6H3,(H2,76,98)(H,79,82)(H,83,111)(H,84,97)(H,85,101)(H,86,106)(H,87,107)(H,88,110)(H,89,104)(H,90,103)(H,91,108)(H,92,109)(H,93,102)(H,94,105)(H,99,100)(H,113,114)(H4,77,78,80)/t39-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	0.140	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of platelet derived growth factor receptor beta phosphorylation in MG63 cells in the presence of human plasma				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM50256277 (CHEMBL4093698) Show SMILES CC(C)C[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSCc3cc(CSC[C@H](NC1=O)C(O)=O)cc(CSC[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)c3 |r| Show InChI InChI=1S/C75H106N20O19S3/c1-37(2)19-50-65(104)89-52(25-45-28-79-36-82-45)67(106)86-49(15-16-60(76)98)64(103)90-53(26-61(99)100)68(107)87-51(20-38(3)4)66(105)94-58(74(113)114)35-117-32-43-22-41-21-42(23-43)31-116-34-57(71(110)88-50)93-63(102)48(13-9-17-80-75(77)78)85-62(101)39(5)83-72(111)59-14-10-18-95(59)73(112)54(24-44-27-81-47-12-8-7-11-46(44)47)91-69(108)55(29-96)92-70(109)56(33-115-30-41)84-40(6)97/h7-8,11-12,21-23,27-28,36-39,48-59,81,96H,9-10,13-20,24-26,29-35H2,1-6H3,(H2,76,98)(H,79,82)(H,83,111)(H,84,97)(H,85,101)(H,86,106)(H,87,107)(H,88,110)(H,89,104)(H,90,103)(H,91,108)(H,92,109)(H,93,102)(H,94,105)(H,99,100)(H,113,114)(H4,77,78,80)/t39-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	0.150	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of human plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins followed by substrate additio...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Protease (Human immunodeficiency virus 1 (HIV-1))	BDBM50480931 (CHEMBL575512 | KNI-1614) Show SMILES CC(=C)CNC(=O)[C@H]1N(CSC1(C)C)C(=O)[C@@H](O)[C@H](Cc1ccccc1)NC(=O)c1cccc(O)c1C |r| Show InChI InChI=1S/C28H35N3O5S/c1-17(2)15-29-26(35)24-28(4,5)37-16-31(24)27(36)23(33)21(14-19-10-7-6-8-11-19)30-25(34)20-12-9-13-22(32)18(20)3/h6-13,21,23-24,32-33H,1,14-16H2,2-5H3,(H,29,35)(H,30,34)/t21-,23-,24+/m0/s1	PDB UniProtKB/TrEMBL B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	0.190	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Kyoto Pharmaceutical University Curated by ChEMBL					Assay Description Inhibition of HIV1 recombinant protease after 15 mins by fluorescence assay				J Med Chem 52: 7604-17 (2009) Article DOI: 10.1021/jm9005115 BindingDB Entry DOI: 10.7270/Q2FR00F2
					More data for this Ligand-Target Pair
Glucocorticoid receptor (Homo sapiens (Human))	BDBM18617 ((18Z)-12-methoxy-18-{[3-(methoxymethyl)thiophen-2-...) Show SMILES COCc1ccsc1\C=C1/Oc2ccc(O)c(OC)c2-c2ccc3NC(C)(C)C=C(C)c3c12 |t:30| Show InChI InChI=1S/C27H27NO4S/c1-15-13-27(2,3)28-18-7-6-17-24(23(15)18)21(12-22-16(14-30-4)10-11-33-22)32-20-9-8-19(29)26(31-5)25(17)20/h6-13,28-29H,14H2,1-5H3/b21-12-	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Patents Similars	Article PubMed	0.200	-51.5	0.200	n/a	0.200	n/a	n/a	7.5	4
Ligand Pharmaceuticals Inc.					Assay Description Competitive Ligand Binding Assay- The Ki values were determined by the application of the Cheng-Prusoff equation: Ki=IC50/(1+[L]/Kd) where [L] is the...				J Med Chem 50: 4699-709 (2007) Article DOI: 10.1021/jm070370z BindingDB Entry DOI: 10.7270/Q2T151XT
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM50256286 (CHEMBL4076199) Show SMILES CC(C)C[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSCc3cc(CSC[C@H](NC1=O)C(O)=O)cc(CSC[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCNC(N)=N)C(=O)N2)c3 |r| Show InChI InChI=1S/C79H109N19O20S3/c1-41(2)23-53-68(107)91-56(30-49-32-83-40-85-49)71(110)88-52(18-19-64(80)102)67(106)92-57(31-65(103)104)72(111)89-54(24-42(3)4)69(108)97-62(78(117)118)39-121-36-48-26-46-25-47(27-48)35-120-38-61(75(114)90-53)96-66(105)51(13-9-10-21-84-79(81)82)87-70(109)55(28-45-14-16-50(101)17-15-45)93-76(115)63-20-22-98(63)77(116)58(29-44-11-7-6-8-12-44)94-73(112)59(33-99)95-74(113)60(37-119-34-46)86-43(5)100/h6-8,11-12,14-17,25-27,32,40-42,51-63,99,101H,9-10,13,18-24,28-31,33-39H2,1-5H3,(H2,80,102)(H,83,85)(H,86,100)(H,87,109)(H,88,110)(H,89,111)(H,90,114)(H,91,107)(H,92,106)(H,93,115)(H,94,112)(H,95,113)(H,96,105)(H,97,108)(H,103,104)(H,117,118)(H4,81,82,84)/t51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	0.210	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of human plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins followed by substrate additio...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM50256262 (CHEMBL4070056) Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@@H]2CSCc3cc(CSC[C@H](NC1=O)C(=O)N[C@@H](C)C(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(O)=O)cc(CSC[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCNC(N)=N)C(=O)N2)c3)C(C)C |r| Show InChI InChI=1S/C114H161N29O28S3/c1-10-62(4)94-107(166)136-85(101(160)124-63(5)108(167)141(9)53-91(151)140(8)52-90(150)139(7)51-89(149)126-75(22-16-39-122-113(117)118)95(154)128-77(111(170)171)23-17-40-123-114(119)120)59-173-56-70-43-69-44-71(45-70)57-174-60-86(103(162)137-93(61(2)3)106(165)131-79(47-67-27-33-73(147)34-28-67)98(157)132-82(49-68-29-35-74(148)36-30-68)109(168)142-41-18-24-87(142)104(163)130-80(50-92(152)153)99(158)138-94)135-96(155)76(21-14-15-38-121-112(115)116)127-97(156)78(46-66-25-31-72(146)32-26-66)129-105(164)88-37-42-143(88)110(169)81(48-65-19-12-11-13-20-65)133-100(159)83(54-144)134-102(161)84(58-172-55-69)125-64(6)145/h11-13,19-20,25-36,43-45,61-63,75-88,93-94,144,146-148H,10,14-18,21-24,37-42,46-60H2,1-9H3,(H,124,160)(H,125,145)(H,126,149)(H,127,156)(H,128,154)(H,129,164)(H,130,163)(H,131,165)(H,132,157)(H,133,159)(H,134,161)(H,135,155)(H,136,166)(H,137,162)(H,138,158)(H,152,153)(H,170,171)(H4,115,116,121)(H4,117,118,122)(H4,119,120,123)/t62-,63-,75+,76-,77+,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88?,93-,94-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	0.25	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of human plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins followed by substrate additio...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP2 subtype (Homo sapiens (Human))	BDBM263346 (US9546162, 4) Show SMILES OC(=O)c1ccc(CCc2cccc3CCN(Cc4cc(cc(c4)C(F)(F)F)C(F)(F)F)c23)cc1 Show InChI InChI=1S/C26H21F6NO2/c27-25(28,29)21-12-17(13-22(14-21)26(30,31)32)15-33-11-10-19-3-1-2-18(23(19)33)7-4-16-5-8-20(9-6-16)24(34)35/h1-3,5-6,8-9,12-14H,4,7,10-11,15H2,(H,34,35)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.300	n/a	n/a	n/a	11	n/a	n/a	7.4	n/a
ALLERGAN, INC. US Patent					Assay Description Cells were seeded at a density of 5×104 cells per well in Biocoat® Poly-D-lysine-coated black-wall, clear-bottom 96-well plates (Becton-Dickinson) an...				US Patent US9546162 (2017) BindingDB Entry DOI: 10.7270/Q2P55QHV
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM50256260 (CHEMBL4094403) Show SMILES CC(C)C[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC[C@H](C)NC(=O)[C@H]2CSCc3cc(CSC[C@H](NC1=O)C(O)=O)cc(CSC[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCNC(N)=N)C(=O)N2)c3 |r| Show InChI InChI=1S/C76H105N19O19S3/c1-40(2)22-53-67(105)94-60(75(113)114)38-117-35-47-24-45-23-46(25-47)34-116-37-59(71(109)84-41(3)30-82-52(28-48-31-80-39-83-48)66(104)87-51(17-18-62(77)99)65(103)89-55(29-63(100)101)69(107)88-53)93-64(102)50(12-8-9-20-81-76(78)79)86-68(106)54(26-44-13-15-49(98)16-14-44)90-73(111)61-19-21-95(61)74(112)56(27-43-10-6-5-7-11-43)91-70(108)57(32-96)92-72(110)58(36-115-33-45)85-42(4)97/h5-7,10-11,13-16,23-25,31,39-41,50-61,82,96,98H,8-9,12,17-22,26-30,32-38H2,1-4H3,(H2,77,99)(H,80,83)(H,84,109)(H,85,97)(H,86,106)(H,87,104)(H,88,107)(H,89,103)(H,90,111)(H,91,108)(H,92,110)(H,93,102)(H,94,105)(H,100,101)(H,113,114)(H4,78,79,81)/t41-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59+,60-,61?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Patents	Article PubMed	0.360	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of human plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins followed by substrate additio...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM50256276 (CHEMBL4079260) Show SMILES CC(C)C[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSCc3cc(CSC[C@H](NC1=O)C(O)=O)cc(CSC[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)c3 |r| Show InChI InChI=1S/C79H109N19O20S3/c1-41(2)23-53-68(107)91-56(30-49-32-83-40-85-49)71(110)88-52(19-20-64(80)102)67(106)92-57(31-65(103)104)72(111)89-54(24-42(3)4)69(108)97-62(78(117)118)39-121-36-48-26-46-25-47(27-48)35-120-38-61(75(114)90-53)96-66(105)51(13-9-21-84-79(81)82)87-70(109)55(28-45-15-17-50(101)18-16-45)93-76(115)63-14-10-22-98(63)77(116)58(29-44-11-7-6-8-12-44)94-73(112)59(33-99)95-74(113)60(37-119-34-46)86-43(5)100/h6-8,11-12,15-18,25-27,32,40-42,51-63,99,101H,9-10,13-14,19-24,28-31,33-39H2,1-5H3,(H2,80,102)(H,83,85)(H,86,100)(H,87,109)(H,88,110)(H,89,111)(H,90,114)(H,91,107)(H,92,106)(H,93,115)(H,94,112)(H,95,113)(H,96,105)(H,97,108)(H,103,104)(H,117,118)(H4,81,82,84)/t51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	0.390	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of human plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins followed by substrate additio...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Plasma kallikrein (Rattus norvegicus)	BDBM50256284 (CHEMBL4075544) Show SMILES CC(C)C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CSCc3cc(CSC[C@H](NC1=O)C(=O)N[C@@H](C)C(O)=O)cc(CSC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N2)c3 |r| Show InChI InChI=1S/C97H124N22O23S3/c1-47(2)28-64-83(127)114-71(88(132)105-50(5)97(141)142)44-143-41-52-29-53-31-54(30-52)43-145-46-73(96(140)119-27-15-24-76(119)92(136)109-65(32-55-38-101-61-19-10-7-16-58(55)61)84(128)107-69(37-79(123)124)82(126)104-49(4)94(138)117-25-13-22-74(117)90(134)108-64)115-86(130)66(33-56-39-102-62-20-11-8-17-59(56)62)110-91(135)75-23-14-26-118(75)95(139)70(36-78(100)122)112-85(129)67(34-57-40-103-63-21-12-9-18-60(57)63)111-93(137)80(51(6)120)116-87(131)68(35-77(99)121)106-89(133)72(45-144-42-53)113-81(125)48(3)98/h7-12,16-21,29-31,38-40,47-51,64-76,80,101-103,120H,13-15,22-28,32-37,41-46,98H2,1-6H3,(H2,99,121)(H2,100,122)(H,104,126)(H,105,132)(H,106,133)(H,107,128)(H,108,134)(H,109,136)(H,110,135)(H,111,137)(H,112,129)(H,113,125)(H,114,127)(H,115,130)(H,116,131)(H,123,124)(H,141,142)/t48-,49-,50-,51+,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,80-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	KEGG PC cid PC sid UniChem Similars	Article PubMed	0.400	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of recombinant Sprague-Dawley rat plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins foll...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP4 subtype (Homo sapiens (Human))	BDBM263361 (US9546162, 19) Show SMILES COc1cc(CO)cc(c1)S(=O)(=O)N1CCc2cccc(CCc3ccc(cc3)C(O)=O)c12 Show InChI InChI=1S/C25H25NO6S/c1-32-22-13-18(16-27)14-23(15-22)33(30,31)26-12-11-20-4-2-3-19(24(20)26)8-5-17-6-9-21(10-7-17)25(28)29/h2-4,6-7,9-10,13-15,27H,5,8,11-12,16H2,1H3,(H,28,29)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.400	n/a	n/a	n/a	2	n/a	n/a	7.4	n/a
ALLERGAN, INC. US Patent					Assay Description HEK-293 cells stably expressing the human or feline FP receptor, or EP1, EP2, or EP4 receptors were washed with TME buffer, scraped from the bottom o...				US Patent US9546162 (2017) BindingDB Entry DOI: 10.7270/Q2P55QHV
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM50256288 (CHEMBL4085408) Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@@H]2CSCc3cc(CSC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N4CCC[C@H]4C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)cc(CSC[C@H](NC1=O)C(=O)N[C@@H](C)C(O)=O)c3)C(C)C |r| Show InChI InChI=1S/C99H132N22O24S3/c1-7-52(4)81-95(141)117-72(89(135)106-54(6)98(144)145)48-146-45-59-35-60-37-61(36-59)47-148-50-74(91(137)118-80(51(2)3)94(140)112-66(39-57-24-28-62(122)29-25-57)85(131)113-71(41-58-26-30-63(123)31-27-58)97(143)121-34-16-23-76(121)93(139)111-69(44-79(126)127)88(134)119-81)116-83(129)64(21-14-32-105-99(103)104)107-84(130)65(38-55-17-10-8-11-18-55)110-92(138)75-22-15-33-120(75)96(142)70(40-56-19-12-9-13-20-56)114-87(133)68(43-78(102)125)108-86(132)67(42-77(101)124)109-90(136)73(49-147-46-60)115-82(128)53(5)100/h8-13,17-20,24-31,35-37,51-54,64-76,80-81,122-123H,7,14-16,21-23,32-34,38-50,100H2,1-6H3,(H2,101,124)(H2,102,125)(H,106,135)(H,107,130)(H,108,132)(H,109,136)(H,110,138)(H,111,139)(H,112,140)(H,113,131)(H,114,133)(H,115,128)(H,116,129)(H,117,141)(H,118,137)(H,119,134)(H,126,127)(H,144,145)(H4,103,104,105)/t52-,53-,54-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,80-,81-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem Similars	Article PubMed	0.440	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of human plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins followed by substrate additio...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Glucocorticoid receptor (Homo sapiens (Human))	BDBM18622 ((18Z)-18-({3-[(1E)-1-(hydroxyimino)ethyl]thiophen-...) Show SMILES COc1c(O)ccc2OC(=Cc3sccc3C(C)N=O)c3c(ccc4NC(C)(C)C=C(C)c34)-c12 |w:10.10,t:30| Show InChI InChI=1S/C27H26N2O4S/c1-14-13-27(3,4)28-18-7-6-17-24(23(14)18)21(12-22-16(10-11-34-22)15(2)29-31)33-20-9-8-19(30)26(32-5)25(17)20/h6-13,15,28,30H,1-5H3	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Patents Similars	Article PubMed	0.600	-48.9	1.10	n/a	5	n/a	n/a	7.5	4
Ligand Pharmaceuticals Inc.					Assay Description Competitive Ligand Binding Assay- The Ki values were determined by the application of the Cheng-Prusoff equation: Ki=IC50/(1+[L]/Kd) where [L] is the...				J Med Chem 50: 4699-709 (2007) Article DOI: 10.1021/jm070370z BindingDB Entry DOI: 10.7270/Q2T151XT
					More data for this Ligand-Target Pair
Glucocorticoid receptor (Homo sapiens (Human))	BDBM18616 ((18Z)-18-{[3-(hydroxymethyl)thiophen-2-yl]methylid...) Show SMILES COc1c(O)ccc2O\C(=C/c3sccc3CO)c3c(ccc4NC(C)(C)C=C(C)c34)-c12 |t:28| Show InChI InChI=1S/C26H25NO4S/c1-14-12-26(2,3)27-17-6-5-16-23(22(14)17)20(11-21-15(13-28)9-10-32-21)31-19-8-7-18(29)25(30-4)24(16)19/h5-12,27-29H,13H2,1-4H3/b20-11-	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Patents Similars	Article PubMed	0.700	-48.6	0.200	n/a	0.200	n/a	n/a	7.5	4
Ligand Pharmaceuticals Inc.					Assay Description Competitive Ligand Binding Assay- The Ki values were determined by the application of the Cheng-Prusoff equation: Ki=IC50/(1+[L]/Kd) where [L] is the...				J Med Chem 50: 4699-709 (2007) Article DOI: 10.1021/jm070370z BindingDB Entry DOI: 10.7270/Q2T151XT
					More data for this Ligand-Target Pair
Delta-type opioid receptor (Homo sapiens (Human))	BDBM50000655 ((4R,7S,10R)-10-[(S)-2-Amino-3-(4-hydroxy-phenyl)-p...) Show SMILES CC1(C)SSC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]1C(O)=O Show InChI InChI=1S/C26H32N4O6S2/c1-26(2)21(25(35)36)30-23(33)19(13-15-6-4-3-5-7-15)28-24(34)20(14-37-38-26)29-22(32)18(27)12-16-8-10-17(31)11-9-16/h3-11,18-21,31H,12-14,27H2,1-2H3,(H,28,34)(H,29,32)(H,30,33)(H,35,36)/t18-,19-,20-,21+/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	0.740	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
University of Michigan Curated by ChEMBL					Assay Description Binding affinity against Opioid receptor delta 1 in guinea pig brain membranes				Bioorg Med Chem Lett 8: 2685-8 (1999) BindingDB Entry DOI: 10.7270/Q2154HJJ
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP4 subtype (Homo sapiens (Human))	BDBM263357 (US9546162, 15) Show SMILES COc1cccc(Cn2ccc3cccc(CCc4ccc(cc4)C(O)=O)c23)c1 Show InChI InChI=1S/C25H23NO3/c1-29-23-7-2-4-19(16-23)17-26-15-14-21-6-3-5-20(24(21)26)11-8-18-9-12-22(13-10-18)25(27)28/h2-7,9-10,12-16H,8,11,17H2,1H3,(H,27,28)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.800	n/a	n/a	n/a	1	n/a	n/a	7.4	n/a
ALLERGAN, INC. US Patent					Assay Description HEK-293 cells stably expressing the human or feline FP receptor, or EP1, EP2, or EP4 receptors were washed with TME buffer, scraped from the bottom o...				US Patent US9546162 (2017) BindingDB Entry DOI: 10.7270/Q2P55QHV
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP4 subtype (Homo sapiens (Human))	BDBM238312 (US9394273, 1 | US9394273, 2) Show SMILES OC(Cc1ccc2ccccc2c1)\C=C\[C@H]1CCC(=O)[C@@H]1CCc1ccc(cc1)C(O)=O |r| Show InChI InChI=1S/C28H28O4/c29-25(18-20-7-9-21-3-1-2-4-24(21)17-20)14-12-22-13-16-27(30)26(22)15-8-19-5-10-23(11-6-19)28(31)32/h1-7,9-12,14,17,22,25-26,29H,8,13,15-16,18H2,(H,31,32)/b14-12+/t22-,25?,26+/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.800	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
ALLERGAN, INC. US Patent					Assay Description The cell homogenate was centrifuged at 19000 r.p.m. for 20 min at 4° C. using a Beckman Ti-60 rotor. The resultant pellet was resuspended in TME buf...				US Patent US9394273 (2016) BindingDB Entry DOI: 10.7270/Q2SJ1JGJ
					More data for this Ligand-Target Pair
Protease (Human immunodeficiency virus 1 (HIV-1))	BDBM50480929 (CHEMBL573975 | KNI-1689) Show SMILES CC(=C)CNC(=O)[C@H]1N(CSC1(C)C)C(=O)[C@@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cc(N)cc1C |r| Show InChI InChI=1S/C30H40N4O5S/c1-18(2)15-32-28(37)27-30(5,6)40-17-34(27)29(38)25(36)23(14-21-10-8-7-9-11-21)33-24(35)16-39-26-19(3)12-22(31)13-20(26)4/h7-13,23,25,27,36H,1,14-17,31H2,2-6H3,(H,32,37)(H,33,35)/t23-,25-,27+/m0/s1	PDB UniProtKB/TrEMBL B.MOAD GoogleScholar AffyNet	PC cid PC sid PDB UniChem	PDB Article PubMed	0.830	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Kyoto Pharmaceutical University Curated by ChEMBL					Assay Description Inhibition of HIV1 recombinant protease after 15 mins by fluorescence assay				J Med Chem 52: 7604-17 (2009) Article DOI: 10.1021/jm9005115 BindingDB Entry DOI: 10.7270/Q2FR00F2
					More data for this Ligand-Target Pair				3D Structure (crystal)
Plasma kallikrein (Rattus norvegicus)	BDBM50256283 (CHEMBL4079711) Show SMILES CC(C)C[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSCc3cc(CSC[C@H](NC1=O)C(=O)N[C@@H](C)C(O)=O)cc(CSC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)c3 |r| Show InChI InChI=1S/C79H114N22O20S3/c1-38(2)20-52-68(110)94-54(26-47-29-84-37-87-47)70(112)91-51(16-17-62(81)103)67(109)95-55(27-63(104)105)71(113)92-53(21-39(3)4)69(111)100-58(73(115)89-42(7)78(120)121)34-122-31-43-22-44-24-45(23-43)33-124-36-60(74(116)93-52)99-66(108)50(14-10-18-85-79(82)83)90-65(107)41(6)88-76(118)61-15-11-19-101(61)77(119)56(25-46-28-86-49-13-9-8-12-48(46)49)96-72(114)57(30-102)97-75(117)59(35-123-32-44)98-64(106)40(5)80/h8-9,12-13,22-24,28-29,37-42,50-61,86,102H,10-11,14-21,25-27,30-36,80H2,1-7H3,(H2,81,103)(H,84,87)(H,88,118)(H,89,115)(H,90,107)(H,91,112)(H,92,113)(H,93,116)(H,94,110)(H,95,109)(H,96,114)(H,97,117)(H,98,106)(H,99,108)(H,100,111)(H,104,105)(H,120,121)(H4,82,83,85)/t40-,41-,42-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	KEGG PC cid PC sid UniChem Similars	Article PubMed	0.900	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of recombinant Sprague-Dawley rat plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins foll...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP4 subtype (Homo sapiens (Human))	BDBM238319 (US9394273, 10 | US9394273, 8 | US9394273, 9) Show SMILES OC(Cc1cccc(Br)c1)\C=C\[C@H]1CCC(=O)[C@@H]1CCc1ccc(cc1)C(O)=O |r| Show InChI InChI=1S/C24H25BrO4/c25-20-3-1-2-17(14-20)15-21(26)11-9-18-10-13-23(27)22(18)12-6-16-4-7-19(8-5-16)24(28)29/h1-5,7-9,11,14,18,21-22,26H,6,10,12-13,15H2,(H,28,29)/b11-9+/t18-,21?,22+/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
ALLERGAN, INC. US Patent					Assay Description The cell homogenate was centrifuged at 19000 r.p.m. for 20 min at 4° C. using a Beckman Ti-60 rotor. The resultant pellet was resuspended in TME buf...				US Patent US9394273 (2016) BindingDB Entry DOI: 10.7270/Q2SJ1JGJ
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP4 subtype (Homo sapiens (Human))	BDBM238322 (US9394273, 11 | US9394273, 12) Show SMILES OC(Cc1cccc(c1)C(F)(F)F)\C=C\[C@H]1CCC(=O)[C@@H]1CCc1ccc(cc1)C(O)=O |r| Show InChI InChI=1S/C25H25F3O4/c26-25(27,28)20-3-1-2-17(14-20)15-21(29)11-9-18-10-13-23(30)22(18)12-6-16-4-7-19(8-5-16)24(31)32/h1-5,7-9,11,14,18,21-22,29H,6,10,12-13,15H2,(H,31,32)/b11-9+/t18-,21?,22+/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
ALLERGAN, INC. US Patent					Assay Description The cell homogenate was centrifuged at 19000 r.p.m. for 20 min at 4° C. using a Beckman Ti-60 rotor. The resultant pellet was resuspended in TME buf...				US Patent US9394273 (2016) BindingDB Entry DOI: 10.7270/Q2SJ1JGJ
					More data for this Ligand-Target Pair
Synaptic vesicular amine transporter (Bos taurus)	BDBM50017712 ((-)-reserpine | (3beta,16beta,17alpha,18beta,20alp...) Show SMILES CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1 |r| Show InChI InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1	PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet	Purchase CHEMBL DrugBank MCE KEGG PC cid PC sid PDB UniChem Patents Similars	PDB Article PubMed	1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Wichita State University Curated by ChEMBL					Assay Description Inhibition of dopamine uptake at VMAT in bovine chromaffin granule ghosts				J Med Chem 51: 760-8 (2008) Article DOI: 10.1021/jm070875p BindingDB Entry DOI: 10.7270/Q2M909J6
					More data for this Ligand-Target Pair				3D Structure (crystal)
Prostaglandin E2 receptor EP4 subtype (Homo sapiens (Human))	BDBM238319 (US9394273, 10 | US9394273, 8 | US9394273, 9) Show SMILES OC(Cc1cccc(Br)c1)\C=C\[C@H]1CCC(=O)[C@@H]1CCc1ccc(cc1)C(O)=O |r| Show InChI InChI=1S/C24H25BrO4/c25-20-3-1-2-17(14-20)15-21(26)11-9-18-10-13-23(27)22(18)12-6-16-4-7-19(8-5-16)24(28)29/h1-5,7-9,11,14,18,21-22,26H,6,10,12-13,15H2,(H,28,29)/b11-9+/t18-,21?,22+/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
ALLERGAN, INC. US Patent					Assay Description The cell homogenate was centrifuged at 19000 r.p.m. for 20 min at 4° C. using a Beckman Ti-60 rotor. The resultant pellet was resuspended in TME buf...				US Patent US9394273 (2016) BindingDB Entry DOI: 10.7270/Q2SJ1JGJ
					More data for this Ligand-Target Pair
Glucocorticoid receptor (Homo sapiens (Human))	BDBM18623 ((18Z)-12-methoxy-18-({3-[(1E)-1-(methoxyimino)ethy...) Show SMILES CO\N=C(/C)c1ccsc1\C=C1/Oc2ccc(O)c(OC)c2-c2ccc3NC(C)(C)C=C(C)c3c12 |t:32| Show InChI InChI=1S/C28H28N2O4S/c1-15-14-28(3,4)29-19-8-7-18-25(24(15)19)22(13-23-17(11-12-35-23)16(2)30-33-6)34-21-10-9-20(31)27(32-5)26(18)21/h7-14,29,31H,1-6H3/b22-13-,30-16+	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Patents Similars	Article PubMed	1.10	-47.5	0.200	n/a	0.100	n/a	n/a	7.5	4
Ligand Pharmaceuticals Inc.					Assay Description Competitive Ligand Binding Assay- The Ki values were determined by the application of the Cheng-Prusoff equation: Ki=IC50/(1+[L]/Kd) where [L] is the...				J Med Chem 50: 4699-709 (2007) Article DOI: 10.1021/jm070370z BindingDB Entry DOI: 10.7270/Q2T151XT
					More data for this Ligand-Target Pair
Glucocorticoid receptor (Homo sapiens (Human))	BDBM18632 ((18Z)-18-{[3-(1-hydroxyethyl)thiophen-2-yl]methyli...) Show SMILES COc1c(O)ccc2O\C(=C/c3sccc3C(C)O)c3c(ccc4NC(C)(C)C=C(C)c34)-c12 |t:29| Show InChI InChI=1S/C27H27NO4S/c1-14-13-27(3,4)28-18-7-6-17-24(23(14)18)21(12-22-16(15(2)29)10-11-33-22)32-20-9-8-19(30)26(31-5)25(17)20/h6-13,15,28-30H,1-5H3/b21-12-	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Patents Similars	Article PubMed	1.20	-47.3	1.60	n/a	1.30	n/a	n/a	7.5	4
Ligand Pharmaceuticals Inc.					Assay Description Competitive Ligand Binding Assay- The Ki values were determined by the application of the Cheng-Prusoff equation: Ki=IC50/(1+[L]/Kd) where [L] is the...				J Med Chem 50: 4699-709 (2007) Article DOI: 10.1021/jm070370z BindingDB Entry DOI: 10.7270/Q2T151XT
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM50256263 (CHEMBL4088185) Show SMILES CC(C)C[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC[C@H](C)NC(=O)[C@@H]2CSCc3cc(CSC[C@H](NC1=O)C(O)=O)cc(CSC[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)c3 |r| Show InChI InChI=1S/C76H105N19O19S3/c1-40(2)22-53-67(105)94-60(75(113)114)38-117-35-47-24-45-23-46(25-47)34-116-37-59(71(109)84-41(3)30-82-52(28-48-31-80-39-83-48)66(104)87-51(18-19-62(77)99)65(103)89-55(29-63(100)101)69(107)88-53)93-64(102)50(12-8-20-81-76(78)79)86-68(106)54(26-44-14-16-49(98)17-15-44)90-73(111)61-13-9-21-95(61)74(112)56(27-43-10-6-5-7-11-43)91-70(108)57(32-96)92-72(110)58(36-115-33-45)85-42(4)97/h5-7,10-11,14-17,23-25,31,39-41,50-61,82,96,98H,8-9,12-13,18-22,26-30,32-38H2,1-4H3,(H2,77,99)(H,80,83)(H,84,109)(H,85,97)(H,86,106)(H,87,104)(H,88,107)(H,89,103)(H,90,111)(H,91,108)(H,92,110)(H,93,102)(H,94,105)(H,100,101)(H,113,114)(H4,78,79,81)/t41-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	1.30	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of platelet derived growth factor receptor beta phosphorylation in MG63 cells in the presence of human plasma				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Glucocorticoid receptor (Homo sapiens (Human))	BDBM18628 ((18Z)-12-methoxy-3,5,5-trimethyl-18-{[3-(2,2,2-tri...) Show SMILES COc1c(O)ccc2O\C(=C/c3sccc3C(O)C(F)(F)F)c3c(ccc4NC(C)(C)C=C(C)c34)-c12 |t:32| Show InChI InChI=1S/C27H24F3NO4S/c1-13-12-26(2,3)31-16-6-5-15-22(21(13)16)19(35-18-8-7-17(32)24(34-4)23(15)18)11-20-14(9-10-36-20)25(33)27(28,29)30/h5-12,25,31-33H,1-4H3/b19-11-	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Patents Similars	Article PubMed	1.40	-47.0	0.400	n/a	0.300	n/a	n/a	7.5	4
Ligand Pharmaceuticals Inc.					Assay Description Competitive Ligand Binding Assay- The Ki values were determined by the application of the Cheng-Prusoff equation: Ki=IC50/(1+[L]/Kd) where [L] is the...				J Med Chem 50: 4699-709 (2007) Article DOI: 10.1021/jm070370z BindingDB Entry DOI: 10.7270/Q2T151XT
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP4 subtype (Homo sapiens (Human))	BDBM238316 (US9394273, 5 | US9394273, 6) Show SMILES OC(Cc1cccc(F)c1)\C=C\[C@H]1CCC(=O)[C@@H]1CCc1ccc(cc1)C(O)=O |r| Show InChI InChI=1S/C24H25FO4/c25-20-3-1-2-17(14-20)15-21(26)11-9-18-10-13-23(27)22(18)12-6-16-4-7-19(8-5-16)24(28)29/h1-5,7-9,11,14,18,21-22,26H,6,10,12-13,15H2,(H,28,29)/b11-9+/t18-,21?,22+/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	2	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
ALLERGAN, INC. US Patent					Assay Description The cell homogenate was centrifuged at 19000 r.p.m. for 20 min at 4° C. using a Beckman Ti-60 rotor. The resultant pellet was resuspended in TME buf...				US Patent US9394273 (2016) BindingDB Entry DOI: 10.7270/Q2SJ1JGJ
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP2 subtype (Homo sapiens (Human))	BDBM263347 (US9546162, 5) Show SMILES COc1cc(CO)cc(CN2CCc3cccc(CCc4ccc(cc4)C(O)=O)c23)c1 Show InChI InChI=1S/C26H27NO4/c1-31-24-14-19(13-20(15-24)17-28)16-27-12-11-22-4-2-3-21(25(22)27)8-5-18-6-9-23(10-7-18)26(29)30/h2-4,6-7,9-10,13-15,28H,5,8,11-12,16-17H2,1H3,(H,29,30)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	2	n/a	n/a	n/a	11	n/a	n/a	7.4	n/a
ALLERGAN, INC. US Patent					Assay Description HEK-293 cells stably expressing the human or feline FP receptor, or EP1, EP2, or EP4 receptors were washed with TME buffer, scraped from the bottom o...				US Patent US9546162 (2017) BindingDB Entry DOI: 10.7270/Q2P55QHV
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP4 subtype (Homo sapiens (Human))	BDBM238336 (US9394273, 25 | US9394273, 26) Show SMILES OC(Cc1cccc(F)c1F)\C=C\[C@H]1CCC(=O)[C@@H]1CCc1ccc(cc1)C(O)=O |r| Show InChI InChI=1S/C24H24F2O4/c25-21-3-1-2-18(23(21)26)14-19(27)11-9-16-10-13-22(28)20(16)12-6-15-4-7-17(8-5-15)24(29)30/h1-5,7-9,11,16,19-20,27H,6,10,12-14H2,(H,29,30)/b11-9+/t16-,19?,20+/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	2	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
ALLERGAN, INC. US Patent					Assay Description The cell homogenate was centrifuged at 19000 r.p.m. for 20 min at 4° C. using a Beckman Ti-60 rotor. The resultant pellet was resuspended in TME buf...				US Patent US9394273 (2016) BindingDB Entry DOI: 10.7270/Q2SJ1JGJ
					More data for this Ligand-Target Pair
Plasma kallikrein (Rattus norvegicus)	BDBM50256277 (CHEMBL4093698) Show SMILES CC(C)C[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSCc3cc(CSC[C@H](NC1=O)C(O)=O)cc(CSC[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)c3 |r| Show InChI InChI=1S/C75H106N20O19S3/c1-37(2)19-50-65(104)89-52(25-45-28-79-36-82-45)67(106)86-49(15-16-60(76)98)64(103)90-53(26-61(99)100)68(107)87-51(20-38(3)4)66(105)94-58(74(113)114)35-117-32-43-22-41-21-42(23-43)31-116-34-57(71(110)88-50)93-63(102)48(13-9-17-80-75(77)78)85-62(101)39(5)83-72(111)59-14-10-18-95(59)73(112)54(24-44-27-81-47-12-8-7-11-46(44)47)91-69(108)55(29-96)92-70(109)56(33-115-30-41)84-40(6)97/h7-8,11-12,21-23,27-28,36-39,48-59,81,96H,9-10,13-20,24-26,29-35H2,1-6H3,(H2,76,98)(H,79,82)(H,83,111)(H,84,97)(H,85,101)(H,86,106)(H,87,107)(H,88,110)(H,89,104)(H,90,103)(H,91,108)(H,92,109)(H,93,102)(H,94,105)(H,99,100)(H,113,114)(H4,77,78,80)/t39-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	2	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of recombinant Sprague-Dawley rat plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins foll...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP4 subtype (Homo sapiens (Human))	BDBM263366 (US9546162, 24) Show SMILES COc1cc(CN2CCc3cc(F)cc(CCc4ccc(cc4)C(O)=O)c23)cc(OC)c1 Show InChI InChI=1S/C26H26FNO4/c1-31-23-11-18(12-24(15-23)32-2)16-28-10-9-21-14-22(27)13-20(25(21)28)8-5-17-3-6-19(7-4-17)26(29)30/h3-4,6-7,11-15H,5,8-10,16H2,1-2H3,(H,29,30)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	2	n/a	n/a	n/a	2	n/a	n/a	7.4	n/a
ALLERGAN, INC. US Patent					Assay Description Cells were seeded at a density of 5×104 cells per well in Biocoat® Poly-D-lysine-coated black-wall, clear-bottom 96-well plates (Becton-Dickinson) an...				US Patent US9546162 (2017) BindingDB Entry DOI: 10.7270/Q2P55QHV
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP2 subtype (Homo sapiens (Human))	BDBM263343 (US9546162, 1) Show SMILES OC(=O)c1ccc(CCc2cccc3CCN(Cc4cccc(F)c4)c23)cc1 Show InChI InChI=1S/C24H22FNO2/c25-22-6-1-3-18(15-22)16-26-14-13-20-5-2-4-19(23(20)26)10-7-17-8-11-21(12-9-17)24(27)28/h1-6,8-9,11-12,15H,7,10,13-14,16H2,(H,27,28)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	2	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
ALLERGAN, INC. US Patent					Assay Description HEK-293 cells stably expressing the human or feline FP receptor, or EP1, EP2, or EP4 receptors were washed with TME buffer, scraped from the bottom o...				US Patent US9546162 (2017) BindingDB Entry DOI: 10.7270/Q2P55QHV
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP4 subtype (Homo sapiens (Human))	BDBM238318 (US9394273, 7) Show SMILES OC(Cc1cccc(Cl)c1)\C=C\[C@H]1CCC(=O)[C@@H]1CCc1ccc(cc1)C(O)=O |r| Show InChI InChI=1S/C24H25ClO4/c25-20-3-1-2-17(14-20)15-21(26)11-9-18-10-13-23(27)22(18)12-6-16-4-7-19(8-5-16)24(28)29/h1-5,7-9,11,14,18,21-22,26H,6,10,12-13,15H2,(H,28,29)/b11-9+/t18-,21?,22+/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	2	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
ALLERGAN, INC. US Patent					Assay Description The cell homogenate was centrifuged at 19000 r.p.m. for 20 min at 4° C. using a Beckman Ti-60 rotor. The resultant pellet was resuspended in TME buf...				US Patent US9394273 (2016) BindingDB Entry DOI: 10.7270/Q2SJ1JGJ
					More data for this Ligand-Target Pair
Glucocorticoid receptor (Homo sapiens (Human))	BDBM18207 ((1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dih...) Show SMILES [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:28,t:24| Show InChI InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	Purchase DrugBank MCE KEGG MMDB PC cid PC sid PDB UniChem Patents Similars	DrugBank PDB Article PubMed	2.10	-46.0	1.40	n/a	0.200	n/a	n/a	7.5	4
Ligand Pharmaceuticals Inc.					Assay Description Competitive Ligand Binding Assay- The Ki values were determined by the application of the Cheng-Prusoff equation: Ki=IC50/(1+[L]/Kd) where [L] is the...				J Med Chem 50: 4699-709 (2007) Article DOI: 10.1021/jm070370z BindingDB Entry DOI: 10.7270/Q2T151XT
					More data for this Ligand-Target Pair				3D Structure (crystal)
Plasma kallikrein (Homo sapiens (Human))	BDBM50256287 (CHEMBL4105318) Show SMILES CC(C)C[C@@H]1NC(=O)[C@@H]2CSCc3cc(CSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc4cnc[nH]4)NC1=O)C(O)=O)cc(CSC[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(N)=N)C(=O)N2)c3 |r| Show InChI InChI=1S/C76H108N20O19S3/c1-38(2)20-51-66(105)90-53(26-46-29-80-37-83-46)68(107)87-50(16-17-61(77)99)65(104)91-54(27-62(100)101)69(108)88-52(21-39(3)4)67(106)95-59(75(114)115)36-118-33-44-23-42-22-43(24-44)32-117-35-58(72(111)89-51)94-64(103)49(14-9-10-18-81-76(78)79)86-63(102)40(5)84-73(112)60-15-11-19-96(60)74(113)55(25-45-28-82-48-13-8-7-12-47(45)48)92-70(109)56(30-97)93-71(110)57(34-116-31-42)85-41(6)98/h7-8,12-13,22-24,28-29,37-40,49-60,82,97H,9-11,14-21,25-27,30-36H2,1-6H3,(H2,77,99)(H,80,83)(H,84,112)(H,85,98)(H,86,102)(H,87,107)(H,88,108)(H,89,111)(H,90,105)(H,91,104)(H,92,109)(H,93,110)(H,94,103)(H,95,106)(H,100,101)(H,114,115)(H4,78,79,81)/t40-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Patents Similars	Article PubMed	2.10	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of human plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins followed by substrate additio...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM50256284 (CHEMBL4075544) Show SMILES CC(C)C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CSCc3cc(CSC[C@H](NC1=O)C(=O)N[C@@H](C)C(O)=O)cc(CSC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N2)c3 |r| Show InChI InChI=1S/C97H124N22O23S3/c1-47(2)28-64-83(127)114-71(88(132)105-50(5)97(141)142)44-143-41-52-29-53-31-54(30-52)43-145-46-73(96(140)119-27-15-24-76(119)92(136)109-65(32-55-38-101-61-19-10-7-16-58(55)61)84(128)107-69(37-79(123)124)82(126)104-49(4)94(138)117-25-13-22-74(117)90(134)108-64)115-86(130)66(33-56-39-102-62-20-11-8-17-59(56)62)110-91(135)75-23-14-26-118(75)95(139)70(36-78(100)122)112-85(129)67(34-57-40-103-63-21-12-9-18-60(57)63)111-93(137)80(51(6)120)116-87(131)68(35-77(99)121)106-89(133)72(45-144-42-53)113-81(125)48(3)98/h7-12,16-21,29-31,38-40,47-51,64-76,80,101-103,120H,13-15,22-28,32-37,41-46,98H2,1-6H3,(H2,99,121)(H2,100,122)(H,104,126)(H,105,132)(H,106,133)(H,107,128)(H,108,134)(H,109,136)(H,110,135)(H,111,137)(H,112,129)(H,113,125)(H,114,127)(H,115,130)(H,116,131)(H,123,124)(H,141,142)/t48-,49-,50-,51+,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,80-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem Similars	Article PubMed	2.30	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of human plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins followed by substrate additio...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Mu-type opioid receptor (GUINEA PIG)	BDBM50071865 ((S)-2-Amino-N-(6-benzyl-1,2,3,4-tetrahydro-quinoli...) Show SMILES Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NC1CCNc2ccc(Cc3ccccc3)cc12 Show InChI InChI=1S/C27H31N3O2/c1-17-12-21(31)13-18(2)22(17)16-24(28)27(32)30-26-10-11-29-25-9-8-20(15-23(25)26)14-19-6-4-3-5-7-19/h3-9,12-13,15,24,26,29,31H,10-11,14,16,28H2,1-2H3,(H,30,32)/t24-,26?/m0/s1	PDB UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	2.60	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
University of Michigan Curated by ChEMBL					Assay Description Binding affinity against mu opioid receptor in guinea pig brain membranes				Bioorg Med Chem Lett 8: 2685-8 (1999) BindingDB Entry DOI: 10.7270/Q2154HJJ
					More data for this Ligand-Target Pair
Mu-type opioid receptor (GUINEA PIG)	BDBM50071865 ((S)-2-Amino-N-(6-benzyl-1,2,3,4-tetrahydro-quinoli...) Show SMILES Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NC1CCNc2ccc(Cc3ccccc3)cc12 Show InChI InChI=1S/C27H31N3O2/c1-17-12-21(31)13-18(2)22(17)16-24(28)27(32)30-26-10-11-29-25-9-8-20(15-23(25)26)14-19-6-4-3-5-7-19/h3-9,12-13,15,24,26,29,31H,10-11,14,16,28H2,1-2H3,(H,30,32)/t24-,26?/m0/s1	PDB UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	2.62	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
University of Michigan Curated by ChEMBL					Assay Description Binding affinity against Opioid receptor kappa 1 in guinea pig brain membranes				Bioorg Med Chem Lett 8: 2685-8 (1999) BindingDB Entry DOI: 10.7270/Q2154HJJ
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM50256261 (CHEMBL4059991) Show SMILES CC(C)C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CSCc3cc(CSC[C@@H](NC1=O)C(=O)N[C@@H](C)C(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(O)=O)cc(CSC[C@H](NC(C)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N2)c3 |r| Show InChI InChI=1S/C117H160N32O28S3/c1-59(2)37-78-100(161)141-86(105(166)129-60(3)111(172)146(9)52-95(156)145(8)51-94(155)144(7)50-93(154)132-76(27-16-32-124-116(120)121)98(159)133-77(115(176)177)28-17-33-125-117(122)123)57-179-54-65-38-64-39-66(40-65)55-180-58-87(114(175)149-36-20-31-90(149)109(170)137-79(41-67-47-126-73-24-13-10-21-70(67)73)101(162)135-83(46-96(157)158)99(160)130-61(4)112(173)147-34-18-29-88(147)107(168)136-78)142-103(164)80(42-68-48-127-74-25-14-11-22-71(68)74)138-108(169)89-30-19-35-148(89)113(174)84(45-92(119)153)140-102(163)81(43-69-49-128-75-26-15-12-23-72(69)75)139-110(171)97(62(5)150)143-104(165)82(44-91(118)152)134-106(167)85(56-178-53-64)131-63(6)151/h10-15,21-26,38-40,47-49,59-62,76-90,97,126-128,150H,16-20,27-37,41-46,50-58H2,1-9H3,(H2,118,152)(H2,119,153)(H,129,166)(H,130,160)(H,131,151)(H,132,154)(H,133,159)(H,134,167)(H,135,162)(H,136,168)(H,137,170)(H,138,169)(H,139,171)(H,140,163)(H,141,161)(H,142,164)(H,143,165)(H,157,158)(H,176,177)(H4,120,121,124)(H4,122,123,125)/t60-,61-,62+,76+,77+,78-,79-,80-,81-,82-,83-,84-,85-,86+,87-,88-,89-,90-,97-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	3	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of human plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins followed by substrate additio...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP4 subtype (Homo sapiens (Human))	BDBM238330 (US9394273, 19 | US9394273, 20) Show SMILES OC(Cc1ccc(F)cc1)\C=C\[C@H]1CCC(=O)[C@@H]1CCc1ccc(cc1)C(O)=O |r| Show InChI InChI=1S/C24H25FO4/c25-20-10-3-17(4-11-20)15-21(26)12-8-18-9-14-23(27)22(18)13-5-16-1-6-19(7-2-16)24(28)29/h1-4,6-8,10-12,18,21-22,26H,5,9,13-15H2,(H,28,29)/b12-8+/t18-,21?,22+/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	3	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
ALLERGAN, INC. US Patent					Assay Description The cell homogenate was centrifuged at 19000 r.p.m. for 20 min at 4° C. using a Beckman Ti-60 rotor. The resultant pellet was resuspended in TME buf...				US Patent US9394273 (2016) BindingDB Entry DOI: 10.7270/Q2SJ1JGJ
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP2 subtype (Homo sapiens (Human))	BDBM263357 (US9546162, 15) Show SMILES COc1cccc(Cn2ccc3cccc(CCc4ccc(cc4)C(O)=O)c23)c1 Show InChI InChI=1S/C25H23NO3/c1-29-23-7-2-4-19(16-23)17-26-15-14-21-6-3-5-20(24(21)26)11-8-18-9-12-22(13-10-18)25(27)28/h2-7,9-10,12-16H,8,11,17H2,1H3,(H,27,28)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	3	n/a	n/a	n/a	11	n/a	n/a	7.4	n/a
ALLERGAN, INC. US Patent					Assay Description HEK-293 cells stably expressing the human or feline FP receptor, or EP1, EP2, or EP4 receptors were washed with TME buffer, scraped from the bottom o...				US Patent US9546162 (2017) BindingDB Entry DOI: 10.7270/Q2P55QHV
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP4 subtype (Homo sapiens (Human))	BDBM238334 (US9394273, 23 | US9394273, 24) Show SMILES OC(Cc1ccc(F)c(F)c1)\C=C\[C@H]1CCC(=O)[C@@H]1CCc1ccc(cc1)C(O)=O |r| Show InChI InChI=1S/C24H24F2O4/c25-21-11-4-16(14-22(21)26)13-19(27)9-7-17-8-12-23(28)20(17)10-3-15-1-5-18(6-2-15)24(29)30/h1-2,4-7,9,11,14,17,19-20,27H,3,8,10,12-13H2,(H,29,30)/b9-7+/t17-,19?,20+/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	3	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
ALLERGAN, INC. US Patent					Assay Description The cell homogenate was centrifuged at 19000 r.p.m. for 20 min at 4° C. using a Beckman Ti-60 rotor. The resultant pellet was resuspended in TME buf...				US Patent US9394273 (2016) BindingDB Entry DOI: 10.7270/Q2SJ1JGJ
					More data for this Ligand-Target Pair
Prostaglandin E2 receptor EP4 subtype (Homo sapiens (Human))	BDBM263343 (US9546162, 1) Show SMILES OC(=O)c1ccc(CCc2cccc3CCN(Cc4cccc(F)c4)c23)cc1 Show InChI InChI=1S/C24H22FNO2/c25-22-6-1-3-18(15-22)16-26-14-13-20-5-2-4-19(23(20)26)10-7-17-8-11-21(12-9-17)24(27)28/h1-6,8-9,11-12,15H,7,10,13-14,16H2,(H,27,28)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	3	n/a	n/a	n/a	7.20	n/a	n/a	7.4	n/a
ALLERGAN, INC. US Patent					Assay Description HEK-293 cells stably expressing the human or feline FP receptor, or EP1, EP2, or EP4 receptors were washed with TME buffer, scraped from the bottom o...				US Patent US9546162 (2017) BindingDB Entry DOI: 10.7270/Q2P55QHV
					More data for this Ligand-Target Pair
Plasma kallikrein (Rattus norvegicus)	BDBM50256261 (CHEMBL4059991) Show SMILES CC(C)C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CSCc3cc(CSC[C@@H](NC1=O)C(=O)N[C@@H](C)C(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(O)=O)cc(CSC[C@H](NC(C)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N2)c3 |r| Show InChI InChI=1S/C117H160N32O28S3/c1-59(2)37-78-100(161)141-86(105(166)129-60(3)111(172)146(9)52-95(156)145(8)51-94(155)144(7)50-93(154)132-76(27-16-32-124-116(120)121)98(159)133-77(115(176)177)28-17-33-125-117(122)123)57-179-54-65-38-64-39-66(40-65)55-180-58-87(114(175)149-36-20-31-90(149)109(170)137-79(41-67-47-126-73-24-13-10-21-70(67)73)101(162)135-83(46-96(157)158)99(160)130-61(4)112(173)147-34-18-29-88(147)107(168)136-78)142-103(164)80(42-68-48-127-74-25-14-11-22-71(68)74)138-108(169)89-30-19-35-148(89)113(174)84(45-92(119)153)140-102(163)81(43-69-49-128-75-26-15-12-23-72(69)75)139-110(171)97(62(5)150)143-104(165)82(44-91(118)152)134-106(167)85(56-178-53-64)131-63(6)151/h10-15,21-26,38-40,47-49,59-62,76-90,97,126-128,150H,16-20,27-37,41-46,50-58H2,1-9H3,(H2,118,152)(H2,119,153)(H,129,166)(H,130,160)(H,131,151)(H,132,154)(H,133,159)(H,134,167)(H,135,162)(H,136,168)(H,137,170)(H,138,169)(H,139,171)(H,140,163)(H,141,161)(H,142,164)(H,143,165)(H,157,158)(H,176,177)(H4,120,121,124)(H4,122,123,125)/t60-,61-,62+,76+,77+,78-,79-,80-,81-,82-,83-,84-,85-,86+,87-,88-,89-,90-,97-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	3.40	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of recombinant Sprague-Dawley rat plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins foll...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair
Kallikrein (Sus scrofa)	BDBM50256277 (CHEMBL4093698) Show SMILES CC(C)C[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSCc3cc(CSC[C@H](NC1=O)C(O)=O)cc(CSC[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c4ccccc14)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)c3 |r| Show InChI InChI=1S/C75H106N20O19S3/c1-37(2)19-50-65(104)89-52(25-45-28-79-36-82-45)67(106)86-49(15-16-60(76)98)64(103)90-53(26-61(99)100)68(107)87-51(20-38(3)4)66(105)94-58(74(113)114)35-117-32-43-22-41-21-42(23-43)31-116-34-57(71(110)88-50)93-63(102)48(13-9-17-80-75(77)78)85-62(101)39(5)83-72(111)59-14-10-18-95(59)73(112)54(24-44-27-81-47-12-8-7-11-46(44)47)91-69(108)55(29-96)92-70(109)56(33-115-30-41)84-40(6)97/h7-8,11-12,21-23,27-28,36-39,48-59,81,96H,9-10,13-20,24-26,29-35H2,1-6H3,(H2,76,98)(H,79,82)(H,83,111)(H,84,97)(H,85,101)(H,86,106)(H,87,107)(H,88,110)(H,89,104)(H,90,103)(H,91,108)(H,92,109)(H,93,102)(H,94,105)(H,99,100)(H,113,114)(H4,77,78,80)/t39-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-/m0/s1	Reactome pathway KEGG UniProtKB/TrEMBL GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	3.60	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Bicycle Therapeutics Limited, Building 900, Babraham Research Campus , Cambridge CB22 3AT , U.K. Curated by ChEMBL					Assay Description Inhibition of pig plasma kallikrein using fluorogenic H-Pro-Phe-Arg-AMC peptide as substrate preincubated for 15 mins followed by substrate addition ...				J Med Chem 61: 2823-2836 (2018) Article DOI: 10.1021/acs.jmedchem.7b01625 BindingDB Entry DOI: 10.7270/Q2862JW6
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 3117 total )  |  Next  |  Last  >>

Jump to: